CDAHFD-induced Rat MASH Model

Anti-Tumor Drug Efficacy Evaluation
Humanized Immune Checkpoint Mouse Models and Efficacy Services
Autoimmune Disease Efficacy Evaluation
Autoimmune Nephropathy Models and Efficacy ServicesAsthma Models and Efficacy ServicesSystemic Lupus Erythematosus (SLE) Models and Efficacy ServicesSjögren's Syndrome Models and Efficacy ServicesNeuroimmune Diseases Models and Efficacy ServicesAutoimmune Dermatoses Models and Efficacy ServicesInflammatory Bowel Disease (IBD) Models and Efficacy ServicesRheumatoid Arthritis (RA) Models and Efficacy ServicesImmune Reconstitution Autoimmune Disease Models and Efficacy Services
Metabolic Disease Efficacy Evaluation
Obesity Models and Efficacy ServicesType II Diabetes Models and Efficacy ServiceType I Diabetes Models and Efficacy ServicesAndrogenetic Alopecia (AGA) Models and Efficacy ServicesMASH Models and Efficacy ServicesChronic Liver Fibrosis Models and Efficacy ServicesAcute Liver Injury Models and Efficacy ServicesCholestasis Models and Efficacy ServicesAlcohol-related Liver Disease (ALD) Models and Efficacy ServicesChronic Kindey Disease (CKD) Models and Efficacy ServicesActue Kindey Disease (AKD) Models and Efficacy ServicesDiabetes Nephropathy (Diabetic Kidney Disease) Models and Efficacy ServicesSarcopenia Models and Efficacy ServicesGout/Hyperuricemia Models and Efficacy ServicesFemale Reproduction Models and Efficacy Services
Neurological Disease Efficacy Evaluation
In Vitro TestingBehavioral AnalysisIn Vivo Drug Efficacy EvaluationIn Vivo Biochemical ExaminingParkinson’s Disease Rat Model
Cardiovascular Diseases Efficacy Evaluation
Heart Failure Models and Efficacy ServicesHypertension Models and Efficacy ServicesAtherosclerosis Models and Efficacy ServicesAdvanced Cardiovascular and Metabolic Complication Models and Efficacy ServicesHyperlipidemia Models and Efficacy ServicesHypertropic Cardiomyopathy Models and Efficacy ServicesStroke Models and Efficacy ServicesThrombosis Models and Efficacy Services
Bioanalytical Services
Phenotyping Services
Oncology PlatformMetabolism PlatformEfficacy and Pathology Platform
Non-GLP Toxicity Assessment Services
Cell Therapy & Gene Therapy Efficacy Evaluation
Disease Rat Models
60% HFD Induced DIO Rat ModelsAdenine-induced Rat CKD Model5/6 Nephrectomy-induced Rat CKD ModelCCL4-induced Chronic Liver Fibrosis Models in SD RatCDAHFD-induced Rat MASH Model45％HFHS+STZ induced Type I Diabetes Models in SD RatOVX-induced Rat Osteoporosis ModelMCAO-induced CIS Model in SD Rat2K1C-induced Hypertension Model in SD Rat

Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), is the progressive inflammatory stage of metabolic dysfunction-associated steatotic liver disease (MASLD). It is characterized by hepatic steatosis (≥5% fat accumulation), inflammation, hepatocyte injury (ballooning), and fibrosis, which can progress to cirrhosis and hepatocellular carcinoma (HCC).


CDAHFD-induced rat MASH model


The choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD)-induced rat model is a widely used preclinical system for studying metabolic dysfunction-associated steatohepatitis (MASH), particularly for investigating steatohepatitis, fibrosis progression, and therapeutic interventions. This model efficiently recapitulates key features of human MASH within a relatively short time frame (6–12 weeks).

 

图片1.png

Fig.1 Body weight and serum ALT, AST, TC, TG, HDL-C and LDL-C of CDAHFD-induced rat MASH model

 

Body weight curve of CDAHFD-induced rat MASH model is shown in Fig. 1A. The serum level of AST and ALT were significantly higher in CDAHFD-induced MASH rats compared to the CD group, while the serum TC, TG, HDL-C, and LDL-C level is lower (Fig. 1B). Data were presented by mean ± SEM, N=8-30. *, p < 0.05; **, p < 0.01; ***, p < 0.001 and ****, p < 0.0001

 

图片2.png

Fig.2 Histological observation of CDAHFD-induced rat MASH model


Obvious lipid droplet deposition and fibrous tissue hyperplasia were observed in liver of CDAHFD-induced rat MASH model via Pathological staining (HE and Sirius Red staining, Fig. 2A). The Liver/body weight ratio of CDAHFD-induced MASH model is higher than that of CD group as well as the kidney/body weight ratio. Data presented by mean ± SEM, N=3. *, p<0.05; **, p<0.01; ***, p<0.001 and ****, p<0.0001.


Pharmacodynamic evaluation Firsocostat(MGL3196) on CDAHFD-induced rat MASH model


图片3.png

Fig.3 Overview of pharmacodynamic evaluation on CDAHFD-induced rat MASH model

 

图片4.png

Fig.4 Body weight of CDAHFD-induced rat MASH model after SAME treatment.


There is no significant difference between the model group and the Firsocostat treated group in body weight. Data were presented by mean ± SEM, N=14-20.

 

图片5.png

Fig.5 Serum ALT, AST, TC, TG, HDL-C and LDL-C of CDAHFD-induced rat MASH model after Firsocostat treatment


Firsocostat administration reduced serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the CDAHFD-induced rat MASH model, whereas triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) profiles remained unaltered. Data were presented by mean ± SEM, N=14-20. *, p < 0.05; **, p < 0.01; ***, p < 0.001 and ****, p < 0.0001.

 

图片6.png 

Fig.6 The Liver/body weight% and kidney/body weight% of CDAHFD-induced rat MASH model after Firsocostat treatment


The Liver/body weight and kidney/body weight of CDAHFD induced rat MASH model decreased after 6 weeks Firsocostat treatment. Data were presented by mean ± SEM, N=8-20. *, p < 0.05; **, p < 0.01; ***, p < 0.001 and ****, p < 0.0001

 

图片7.png

Fig.7 Histological observation of CDAHFD induced rat MASH model after Firsocostat treatment


After six weeks of Firsocostat administration, no significant improvement in the histopathological NAFLD activity score was observed in CDAHFD-induced rat MASH models (Fig. 7A). However, significant reductions in fibrosis score and α-SMA mRNA expression were detected, suggesting a selective antifibrotic effect (Fig. 7B). Data were presented by mean ± SEM, N=6. *, p < 0.05; **, p < 0.01; ***, p < 0.001 and ****, p < 0.0001

TALK WITH OUR EXPERTS

GemPharmatech is committed to protecting and respecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please click below to say how you would like us to contact you:

In order to provide you with the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please click the checkbox below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.